Efficacy of Everolimus-containing Chemotherapy in HER2- mBC Patients With PI3K/AKT/mTOR Mutations Study

NCT05054166 · clinicaltrials.gov ↗

COMPLETED

Status

14

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer
PI3K/AKT/mTOR Pathway Mutation
Everolimus

Interventions

OTHER: No intervention, it was a retrospective study.

Sponsor

Zhejiang Cancer Hospital